REFERENCES
  1. Kim Carollo (September 10, 2010). Botox and Other Off-Label Treatments for Migraines. ABC News
  2. Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1094-100. doi: 10.1002/pds.1825.
  3. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011 Apr;8(4):e1000431. doi: 10.1371/journal.pmed.1000431. Epub 2011 Apr 5.
  4. Lena Groeger, Feb. 24, 2014. Big Pharma’s Big Fines. ProPublica (Accessed December 2016)
  5. Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol. 2006 Apr;26(2):167-71.
  6. The United States Department of Justice. November 4, 2013. Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations. www.justice.gov. (Accessed November 2016)
  7. The United States Department of Justice. October 17, 2016. Nation’s Largest Nursing Home Pharmacy to Pay Over $28 Million to Settle Kickback Allegations. www.justice.gov. (Accessed October 2016)
  8. The United States Department of Justice. September 2, 2009. Justice Department Announces Largest Health Care Fraud Settlement in Its History. www.justice.gov. (Accessed November 2016)
  9. The United States Department of Justice. January 15, 2009. Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa. www.justice.gov. (Accessed December 2016)
  10. The United States Department of Justice, Fraud Statistics – Overview, Sept. 20, 2010 at 9. Taxpayers against Fraud. Retrieved from: http://www.taf.org/FCA-stats-2010.pdf